J2779 – Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ2779
- Long description
- Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
- Short description
- Inj, susvimo 0.1 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- ASC
- Approved for ambulatory surgical centers
- Added
- July 1, 2022
- Last change
- July 1, 2022 – No change
Frequently asked questions
What is HCPCS code J2779?
J2779 is a HCPCS Level II code for injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg.
Does Medicare cover J2779?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J2724 – Injection, protein c concentrate, intravenous, human, 10 iu
- J2725 – Injection, protirelin, per 250 mcg
- J2730 – Injection, pralidoxime chloride, up to 1 gm
- J2760 – Injection, phentolamine mesylate, up to 5 mg
- J2765 – Injection, metoclopramide hcl, up to 10 mg
- J2770 – Injection, quinupristin/dalfopristin, 500 mg (150/350)
- J2777 – Injection, faricimab-svoa, 0.1 mg
- J2778 – Injection, ranibizumab, 0.1 mg
- J2780 – Injection, ranitidine hydrochloride, 25 mg
- J2781 – Injection, pegcetacoplan, intravitreal, 1 mg
- J2782 – Injection, avacincaptad pegol, 0.1 mg
- J2783 – Injection, rasburicase, 0.5 mg
- J2785 – Injection, regadenoson, 0.1 mg
- J2786 – Injection, reslizumab, 1 mg
- J2787 – Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml
- J2788 – Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.)
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.